1-3 of 3
Arne Muessig, MD
Close
Sort by
Journal Articles

NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy.

Chiara Gentilini, MD, Matthias Haegele, Arne Muessig, MD, Axel Nogai, MD, Constanze Kliem, MD, Kristina Bartsch, MD, Nadezda Bazara, Wichard Vogel, MD, Christoph Faul, MD, Lothar Kanz, MD, Eckhard Thiel, Dietger W. Niederwieser, Lutz Uharek, Wolfgang A. Bethge, MD
Journal: Blood
Blood (2007) 110 (11): 2988.
https://doi.org/10.1182/blood.V110.11.2988.2988
Published: 2007
Journal Articles

Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation.

Chiara Gentilini, MD, Anne Letsch, MD, Annemarie Asemissen, MD, Arne Muessig, MD, Katrin Rieger, MD, Carmen Scheibenbogen, Eckhard Thiel, Lutz Uharek
Journal: Blood
Blood (2006) 108 (11): 3683.
https://doi.org/10.1182/blood.V108.11.3683.3683
Published: 2006
Journal Articles

Alemtuzumab but Not ATG Decreases Natural Killer (NK) Cell Activity towards Tumor Targets in the Early Phase after Allogeneic Stem Cell Transplantation.

Olaf Penack, MD, Lars Fischer, MD, Andrea Stroux, Chiara Gentilini, MD, Axel Nogai, MD, Arne Muessig, MD, Susanne Ganepola, MD, Eckhard Thiel, MD, Lutz Uharek, MD
Journal: Blood
Blood (2006) 108 (11): 2869.
https://doi.org/10.1182/blood.V108.11.2869.2869
Published: 2006